Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol.
Nicholas D. James(Royal Marsden NHS Foundation Trust), Emma Gray(Wellcome Sanger Institute), John M. Russell, Carys Thomas(Cancer Research UK), Silke Gillessen(Institute of Oncology Research), Ruth E. Langley(MRC Clinical Trials Unit at UCL), Jo Bowen(Cancer Research UK), Mahesh Parmar(University College London), Jacob Tanguay(Velindre Cancer Centre), Adrian Cook(University College London), Laura Murphy(Brigham and Women's Hospital), Angus Robinson(Royal Sussex County Hospital), John Wagstaff(Maastricht University Medical Centre), Anjali Zarkar(Cancer Research UK), Narayanan Srihari(Shrewsbury and Telford Hospital NHS Trust), David P. Dearnaley(Royal Marsden NHS Foundation Trust), George N. Thalmann(University Hospital of Bern), Malcolm D. Mason(Royal Marsden Hospital), William Cross(Leeds Teaching Hospitals NHS Trust), Claire Amos(MRC Clinical Trials Unit at UCL), Anna Lydon(Torbay and South Devon NHS Foundation Trust), Clare Gilson(Cancer Research UK), Robert J. Jones(Beatson West of Scotland Cancer Centre), Joe M. O’Sullivan(San Antonio College), Ian Pedley, Matthew R. Sydes(MRC Clinical Trials Unit at UCL), Joanna Gale(Queen Alexandra Hospital), Omi Parikh(Royal Blackburn Teaching Hospital), Noel W. Clarke(The Christie NHS Foundation Trust), David Matheson(MRC Clinical Trials Unit at UCL), Johann S. de Bono(Royal Marsden NHS Foundation Trust), Duncan C. Gilbert(Royal Sussex County Hospital), Cheryl Pugh(MRC Clinical Trials Unit at UCL), Alison Birtle(University of Lancashire), Hannah Rush(University College London), Louise Brown(North Manchester General Hospital), Isabel Syndikus(San Antonio College), Nafisah B Atako(MRC Clinical Trials Unit at UCL), Chris Brawley(Cancer Research UK), James Wylie(Cancer Research UK), Zafar Malik(Cancer Research UK), Christopher Parker(Royal Marsden NHS Foundation Trust), Michelle Buckner(MRC Clinical Trials Unit at UCL), Simon Chowdhury(Sarah Cannon Research Institute), Prantik Das(Royal Derby Hospital), Robin Millman(MRC Clinical Trials Unit at UCL)
Cited by 311
Related Papers
Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
|New England Journal of Medicine|2013|3.3k
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
|New England Journal of Medicine|2012|2.8k
Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis
|Nature|2011|2.8k
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
|New England Journal of Medicine|2015|2.2k